SCM
VNDA icon

Stonepine Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Stonepine Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-195,000
Closed -$973K – 86
2025
Q3 		$973K Sell
195,000
-55,000
-22% -$255K 0.79% 29
2025
Q2 		$1.18M Buy
250,000
+214,852
+611% +$939K 1.16% 23
2025
Q1 		$161K Buy
35,148
+10,148
+41% +$47.3K 0.16% 53
2024
Q4 		$120K Buy
+25,000
New +$120K 0.1% 46
2023
Q4 		– Sell
-477,903
Closed -$2.06M – 21
2023
Q3 		$2.06M Buy
+477,903
New +$2.66M 0.69% 22
2019
Q3 		– Sell
-1,341,943
Closed -$18.9M – 28
2019
Q2 		$18.9M Buy
1,341,943
+81,655
+6% +$1.3M 13.02% 2
2019
Q1 		$23.2M Buy
1,260,288
+1,039,440
+471% +$23.7M 13.34% 1
2018
Q4 		$5.77M Sell
220,848
-103,752
-32% -$2.44M 5.07% 8
2018
Q3 		$7.45M Sell
324,600
-275,400
-46% -$5.62M 4.36% 8
2018
Q2 		$11.4M Sell
600,000
-384,584
-39% -$6.43M 6.95% 5
2018
Q1 		$16.6M Buy
984,584
+99,584
+11% +$1.67M 8.89% 4
2017
Q4 		$13.5M Buy
885,000
+585,000
+195% +$8.68M 8.06% 4
2017
Q3 		$5.37M Sell
300,000
-385,086
-56% -$6.44M 3.17% 14
2017
Q2 		$11.2M Buy
685,086
+641,786
+1,482% +$9.25M 6.03% 5
2017
Q1 		$606K Buy
+43,300
New +$617K 0.34% 20
2016
Q3 		– Sell
-811,563
Closed -$9.08M – 21
2016
Q2 		$9.08M Sell
811,563
-1,256,734
-61% -$12.2M 9.31% 4
2016
Q1 		$17.3M Buy
2,068,297
+149,368
+8% +$1.23M 20.39% 2
2015
Q4 		$17.9M Buy
+1,918,929
New +$19.1M 20.93% 1

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Stonepine Capital Management's VNDA Position: Q4 2025 in Review

Stonepine Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 195,000 shares — an estimated $973K sold.

Stonepine Capital Management first reported a position in VNDA in Q4 2015 and held it in 18 quarters. The position peaked at $23.2M in Q1 2019. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

  • Stonepine Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 195,000 Vanda Pharmaceuticals shares in Q4 2025, an estimated $973K.
  • Stonepine Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 18 quarters.
  • Stonepine Capital Management's Vanda Pharmaceuticals position peaked at $23.2M in Q1 2019.
  • 153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.